
OPAL significantly improves liver function and clinical scores in ACLF patients. In this study with 87 patients (22 OPAL, 41 Prometheus, 24 hemodialysis), OPAL reduced bilirubin (p = 0.0001) and creatinine (p = 0.049) levels, and significantly lowered the MELD score (p = 0.001) and CLIF-C ACLF score (p = 0.0005). OPAL and Prometheus showed stronger reductions in biochemical variables than SMT, with higher survival rates at 14 and 30 days in Prometheus (p = 0.0008 and 0.03).
Like
Save
Share